VERVE-102 gene editing: Can it replace daily statins?
VERVE-102 tests a one‑time CRISPR base‑editing shot to disable PCSK9 in the liver and cut LDL for years. This article breaks down the early Phase‑1 data, what we actually know about safety and durability, and why proven, cheap statins will still be the default for most patients.